{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T12:01:12Z","timestamp":1773403272976,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.msard.2023.104852","type":"journal-article","created":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T01:04:35Z","timestamp":1687914275000},"page":"104852","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Epidemiologic and clinical characteristics of neuromyelitis optica spectrum disorder patients, A seven years follow-up study from Iran"],"prefix":"10.1016","volume":"77","author":[{"given":"Fereshteh","family":"Ashtari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4622-1231","authenticated-orcid":false,"given":"Roshanak","family":"Mehdipour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Eini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arshia","family":"Ghalamkari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2023.104852_bib0001","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1186\/s12889-021-12326-y","article-title":"Non-communicable diseases in the southwest of Iran: profile and baseline data from the Shahrekord PERSIAN Cohort Study","volume":"21","author":"Ahmadi","year":"2021","journal-title":"BMC Public Health"},{"key":"10.1016\/j.msard.2023.104852_bib0002","article-title":"Epidemi-ology of neuromyelitis optica in Latin America","volume":"3","author":"Alvarenga","year":"2017","journal-title":"MultScler J Exp Transl Clin"},{"key":"10.1016\/j.msard.2023.104852_bib0003","doi-asserted-by":"crossref","first-page":"885","DOI":"10.3390\/brainsci12070885","article-title":"NMOSD Diagnostic Dilemmas Leading towards Final Diagnosis","volume":"12","author":"Anna","year":"2022","journal-title":"Brain Sci"},{"key":"10.1016\/j.msard.2023.104852_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2018.02.019","article-title":"An 8-year study of people with multiple sclerosis in Isfahan, Iran: association between environmental air pollutants and severity of disease","author":"Ashtari","year":"2018","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2023.104852_bib0005","unstructured":"Ashtari F., Mehdipour R. The Impact Of COVID-19 Pandemic On Neuromyelitis Optica Disorder Patients, After One Year. Caspian Journal of Neurological. https:\/\/doi.org\/10.32598\/CJNS.8.29."},{"key":"10.1016\/j.msard.2023.104852_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102252","article-title":"Pre-pregnancy, obstetric and delivery status in women with neuromyelitis optica spectrum disorder","volume":"44","author":"Ashtari","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2023.104852_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102685","article-title":"Frequency of comorbidities in Neuromyelitis Optica spectrum disorder","volume":"48","author":"Barzegar","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2023.104852_bib0008","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.msard.2018.12.028","article-title":"Neuromyelitis optica spectrum disorder presenting with concurrent autoimmune diseases","volume":"28","author":"Bibica","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2023.104852_bib0009","doi-asserted-by":"crossref","DOI":"10.1002\/acn3.51683","article-title":"Effects of pregnancy on neuromyelitis optica spectrum disorder and predictors of related attacks","author":"Du","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.msard.2023.104852_bib0010","article-title":"Burden and cost of comorbidities in patients with neuromyelitis optica spectrum disorder","volume":"427","author":"Exuzides","year":"2021","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2023.104852_bib0011","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.msard.2019.06.013","article-title":"Disease course, progression and activity of neuromyelitis optica (NMOSD) in patients who were treated with Rituximab, 6 and 12 months after receiving the first dose of drug, in Isfahan city","volume":"34","author":"Fereshteh","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2023.104852_bib0012","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3390\/neurolint14010023","article-title":"Neuromyelitis Optica Spectrum Disorder in Central America and the Caribbean: a Multinational Clinical Characterization Study","volume":"14","author":"Fernando","year":"2022","journal-title":"Neurol. Int."},{"key":"10.1016\/j.msard.2023.104852_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/NXI.0000000000000363","article-title":"Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS","volume":"4","author":"Gahlen","year":"2017","journal-title":"Neurol. Neuroimmunol. NeuroInflamm."},{"key":"10.1016\/j.msard.2023.104852_bib0014","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1136\/jnnp-2012-302310","article-title":"Current concept of neuromyelitis optica(NMO) and NMO spectrum disorders","volume":"84","author":"Jacob","year":"2013","journal-title":"J Neurol Neuro-surg Psychiatry"},{"key":"10.1016\/j.msard.2023.104852_bib0015","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/cei.12271","article-title":"Neuromyelitis optica: clinical fea-tures, immunopathogenesis and treatment","volume":"176","author":"Jarius","year":"2014","journal-title":"Clin. Exp. Immunol."},{"issue":"10","key":"10.1016\/j.msard.2023.104852_bib0016","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1002\/acn3.51451","article-title":"A meta-analysis comparing first-line immunosuppressants in neuromyelitis optica","volume":"8","author":"Jonathan","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.msard.2023.104852_bib0017","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1177\/1352458511404917","article-title":"Brain abnormalities as an initial manifestation of neuromyelitis optica spectrum disorder","volume":"17","author":"Kim","year":"2011","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.104852_bib0018","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1055\/s-0042-1750081","article-title":"Neuromyelitis Optica Spectrum Disorders in Black African: experience of Togo (2015\u20132020)","volume":"13","author":"Kossivi","year":"2022","journal-title":"J Neurosci Rural Pract"},{"key":"10.1016\/j.msard.2023.104852_bib0019","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1212\/WNL.0b013e31822facdd","article-title":"Incidence of acquired CNS demyelinating syndromes in a multiethnic cohort of children","volume":"77","author":"Langer-Gould","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.104852_bib0020","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1001\/archneurol.2012.314","article-title":"Epidemiology of neuromyelitis optica in the United States: a multicenter analysis","volume":"69","author":"Mealy","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.msard.2023.104852_bib0021","doi-asserted-by":"crossref","first-page":"e01338","DOI":"10.1002\/brb3.1338","article-title":"Epidemiology of neuromyelitis optica spectrum disorder in Denmark (1998\u20132008, 2007\u20132014)","volume":"9","author":"Nasrin Asgari","year":"2019","journal-title":"Brain Behav"},{"issue":"4","key":"10.1016\/j.msard.2023.104852_bib0022","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/practneurol-2012-000237","article-title":"A practical guide to the treatment of neuromyelitis optica","volume":"12","author":"Palace","year":"2012","journal-title":"Pract. Neurol."},{"key":"10.1016\/j.msard.2023.104852_bib0023","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/jamaneurol.2014.1581","article-title":"Seroprevalence of aquaporin-4-IgG in a Northern California population representative cohort of multiple sclerosis","volume":"71","author":"Pittock","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2023.104852_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103083","article-title":"Status of the neuromyelitis optica spectrum disorder in Latin America","volume":"53","author":"Rivera","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2023.104852_bib0025","first-page":"22","article-title":"Cases of neuromyelitis optica spectrum disorder from the East Africa region, highlighting challenges in diagnostics and healthcare access","author":"Sokhi","year":"2021","journal-title":"eNeurologicalSci"},{"key":"10.1016\/j.msard.2023.104852_bib0026","first-page":"325","article-title":"Neuromyelitis optica (NMO) and autoimmune thyroiditis","author":"Sreenivasa","year":"2015","journal-title":"Oxf Med Case Reports"},{"issue":"4","key":"10.1016\/j.msard.2023.104852_bib0027","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1055\/s-0041-1735826","article-title":"Etiological and Radiological Spectrum of Longitudinal Myelitis: a Hospital-Based Study in North East India","volume":"12","author":"Synmon","year":"2021","journal-title":"J Neurosci Rural Pract"},{"key":"10.1016\/j.msard.2023.104852_bib0028","doi-asserted-by":"crossref","DOI":"10.1177\/0883073812451495","article-title":"The Spectrum of Neuromyelitis Optica (NMO) in Childhood","volume":"27","author":"Tillema","year":"2012","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.msard.2023.104852_bib0029","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11910-019-1015-y","article-title":"Atypical Pediatric Demyelinating Diseases of the Central Nervous System","volume":"19","author":"Troxell1","year":"2019","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.msard.2023.104852_bib0030","doi-asserted-by":"crossref","first-page":"e74773","DOI":"10.1371\/journal.pone.0074773","article-title":"Anti-Aquaporin-1 Autoantibodies in Patients with Neuromyelitis Optica Spectrum Disorders","volume":"8","author":"Tzartos","year":"2013","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.msard.2023.104852_bib0031","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.25438","article-title":"Analysis of Pregnancy-Related Attacks in Neuromyelitis Optica Spectrum Disorder, A Systematic Review and Meta-Analysis","volume":"5","author":"Wang","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.msard.2023.104852_bib0032","first-page":"1","article-title":"Short segment myelitis as the initial and only manifestation of aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorders","volume":"13","author":"Wei Fang","year":"2020","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.msard.2023.104852_bib0033","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diag-nostic criteria for neuromyelitis optica spectrum disor-ders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.104852_bib0034","article-title":"Neuromyelitis Optica With Onset in Childhood and Adolescence","author":"Yara Dadalti","year":"2014","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.msard.2023.104852_bib0035","first-page":"1647e1656","article-title":"Treatment response, risk of relapse and clinical characteristics of Taiwanese patients with neuromyelitis optica spectrum disorder","volume":"121","author":"Yi-Hong","year":"2022","journal-title":"J. Formos. Med. Assoc."},{"key":"10.1016\/j.msard.2023.104852_bib0036","article-title":"Incidence of neuromyelitis optica spectrum disorders in China: a large cohort study using claim data","volume":"12","author":"Yiqun","year":"2022","journal-title":"BMJ Open"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823003541?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823003541?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T14:09:25Z","timestamp":1737641365000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034823003541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":36,"alternative-id":["S2211034823003541"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.104852","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epidemiologic and clinical characteristics of neuromyelitis optica spectrum disorder patients, A seven years follow-up study from Iran","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.104852","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104852"}}